Journal article
The risk of progression to type 1 diabetes is highly variable in individuals with multiple autoantibodies following screening
Laura M Jacobsen, Laura Bocchino, Carmella Evans-Molina, Linda DiMeglio, Robin Goland, Darrell M Wilson, Mark A Atkinson, Tandy Aye, William E Russell, John M Wentworth, David Boulware, Susan Geyer, Jay M Sosenko
Diabetologia | SPRINGER | Published : 2020
Abstract
AIMS/HYPOTHESIS: Young children who develop multiple autoantibodies (mAbs) are at very high risk for type 1 diabetes. We assessed whether a population with mAbs detected by screening is also at very high risk, and how risk varies according to age, type of autoantibodies and metabolic status. METHODS: Type 1 Diabetes TrialNet Pathway to Prevention participants with mAbs (n = 1815; age, 12.35 ± 9.39 years; range, 1-49 years) were analysed. Type 1 diabetes risk was assessed according to age, autoantibody type/number (insulin autoantibodies [IAA], glutamic acid decarboxylase autoantibodies [GADA], insulinoma-associated antigen-2 autoantibodies [IA-2A] or zinc transporter 8 autoantibodies [ZnT8A]..
View full abstractGrants
Awarded by NIDDK NIH HHS
Awarded by TrialNet is supported by NIH and JDRF